phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
Vallis K., Reilley R., Scollard D., Petronis J., Caldwell C., Hendler A., Lockwood G., Oza A.